Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 5/2011

01-05-2011 | Gynecologic Oncology

Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment

Authors: Kaei Nasu, Wakana Abe, Noriyuki Takai, Kenichiro Tomonari, Hisashi Narahara

Published in: Archives of Gynecology and Obstetrics | Issue 5/2011

Login to get access

Abstract

Purpose

The aims of this study were to compare the usefulness and reliability of integrated whole-body positron emission tomography/computed tomography (PET/CT) using 18F-fluorodeoxyglucose (FDG) with those of contrast-enhanced multidetector CT during regular follow-up in patients after initial treatment of ovarian cancer, to assess the impact of FDG–PET/CT on the confirmation of recurrence, restaging, and clinical management of patients, and to determine the incremental information provided by PET/CT.

Methods

A retrospective review was performed on 19 ovarian cancer patients who underwent a total of 30 FDG–PET/CT and contrast-enhanced multidetector CT scans. The following information was obtained: the clinical information of the patients; the results of FDG–PET/CT and contrast-enhanced multidetector CT, particularly with regard to the impact on the diagnosis of recurrence; information on the localization and number of diseases; and the impact on subsequent clinical management.

Results

Both FDG–PET/CT and contrast-enhanced multidetector CT had very high sensitivity and specificity for the detection of recurrent ovarian cancer. Contrast-enhanced multidetector CT was considered the more accurate imaging modality for detecting recurrence, whereas FDG–PET/CT was proven more effective for detecting large numbers of small lesions. When comparing the impact on the choice of a management plan, both FDG–PET/CT and contrast-enhanced multidetector CT were found to be significantly effective at predicting the locations of recurrence.

Conclusions

Both integrated FDG–PET/CT and contrast-enhanced multidetector CT are sensitive surveillance modalities for the detection of recurrent ovarian cancer; the use of both modalities aids decisions on treatment plans and may ultimately have a favorable impact on prognosis. However, contrast-enhanced multidetector CT is recommended for the regular follow-up for ovarian cancer patients after initial treatment.
Literature
1.
Heintz A, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S (2001) Carcinoma of the ovary. J Epidemiol Biostat 6:107–138PubMed
2.
Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33(Suppl 6):3–11CrossRef
3.
Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223:495–499PubMedCrossRef
4.
Pannu HK, Bristow RE, Montz FJ, Fishman EK (2003) Multidetector CT of peritoneal carcinomatosis from ovarian cancer. RadioGraphics 23:687–701PubMedCrossRef
5.
Forstner R (2007) Radiographical staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 17:3223–3235PubMedCrossRef
6.
Topuz E, Aydiner A, Saip P, Eralp Y, Tas F, Salihoglu Y, Tenekeci N (2000) Correlation of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol 21:599–602PubMed
7.
Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Buell U, Rath W (2001) 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83:310–315PubMedCrossRef
8.
Kubik-Huch RA, Dorffler W, Von Schulthess GK, Marincek B, Köchli OR, Seifert B, Haller U, Steinert HC (2000) Value of (18F)-FDG positron emission tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur J Radiol 10:761–767CrossRef
9.
Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL (2004) PET–CT detection of abdominal recurrence of ovarian cancer: radiologic–surgical correlation. Abdom Imaging 39:398–403
10.
Bristow RE, Del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, Wahl RL, Montz FJ (2003) Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 90:519–528PubMedCrossRef
11.
Buy JN, Moss AA, Ghossain MA, Sciot C, Malbec L, Vadrot D, Paniel BJ, Decroix Y (1988) Peritoneal implants from ovarian tumors: CT findings. Radiology 169:691–694PubMed
12.
Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, Callet N, Alexandre J, Pecking AP, Alberini JL (2008) Impact of FDG PET–CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 108:160–165PubMedCrossRef
13.
Bristow RE, Giuntoli RL II, Pannu HK, Schulick RD, Fishman EK, Wahl RL (2005) Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 99:294–300PubMedCrossRef
14.
Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB, Lee HP (2007) Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 34:480–486PubMedCrossRef
15.
Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, Bettinardi V, Crivellaro C, Messa C, Fazio F (2007) Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 34:658–666PubMedCrossRef
16.
Thrall MM, DeLoia JA, Gallion H, Avril N (2007) Clinical use of combined positron emission tomography and computed tomography (FDG–PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105:17–22PubMedCrossRef
17.
Togashi K (2003) Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiol 13(Suppl 4):L87–L104PubMedCrossRef
18.
Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC (2002) Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 85:53–58PubMedCrossRef
19.
Martinez-Roman S, Ramirez PT, Oh J, Viciedo MG, MacApinlac HA (2005) Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 96:888–891PubMedCrossRef
20.
Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ (2006) The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 103:271–276PubMedCrossRef
21.
Mansueto M, Grimaldi A, Mangili G, Picchio M, Giovacchini G, Viganò R, Messa C, Fazio F (2009) Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. Eur J Cancer Care 18:612–619CrossRef
Metadata
Title
Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment
Authors
Kaei Nasu
Wakana Abe
Noriyuki Takai
Kenichiro Tomonari
Hisashi Narahara
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 5/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1568-0

Other articles of this Issue 5/2011

Archives of Gynecology and Obstetrics 5/2011 Go to the issue

Materno-fetal Medicine

An analysis of HELLP syndrome cases: does platelet count predict adverse maternal and fetal outcomes in women with HELLP syndrome?

Gynecologic Oncology

Sarcomatoid squamous cell carcinoma of the vulva expressing smooth muscle actin and S100 protein

Materno-Fetal Medicine

Neural networks prediction of preterm delivery with first trimester bleeding

Letter to the Editor

Giant peripheral primitive neuroectodermal tumor of the mons pubis: a case report

Materno-fetal Medicine

Evaluation of ductus venosus and inferior vena cava by using multiple Doppler ultrasound parameters in healthy fetuses

General Gynecology

94 months follow-up after laparoscopic assisted vaginal resection of septum rectovaginale and rectosigmoid in women with deep infiltrating endometriosis